Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as a sterile lyophilized powder for intravenous infusion use. It treats metastatic colorectal cancer in adult patients. GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan Kabi is a topoisomerase I inhibitor used in the management of colorectal cancer. - Metastatic colorectal cancer: used in combination chemotherapy regimens to improve overall survival and disease control.

Irinotecan Kabi may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: may be severe and require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: often managed with antiemetics. - Fatigue: general tiredness experienced during treatment.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis or intestinal perforation due to intense diarrhea. - Hepatic toxicity: elevated liver enzymes or jaundice. - Anaphylactic reactions: rare but potentially life‑threatening hypersensitivity. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should consider several safety measures. - Dose adjustment in hepatic impairment: reduce dose based on bilirubin and liver function tests. - Monitor blood counts: perform regular CBC to detect neutropenia early. - Assess for diarrhea: initiate prophylactic antidiarrheal agents and educate patients. - Avoid concurrent strong CYP3A4 inhibitors: may increase irinotecan exposure and toxicity. - Pregnancy and lactation: use only if potential benefit justifies the unknown risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Irinotecan can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase irinotecan plasma levels. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): raise SN‑38 exposure and risk of neutropenia. - Concurrent myelosuppressive agents (e.g., cyclophosphamide): heighten bone‑marrow suppression. - Live vaccines: immunosuppression may lead to uncontrolled infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug exposure and reduce efficacy. - Warfarin: irinotecan can potentiate anticoagulant effect, requiring INR monitoring. - Antacids or supplements containing magnesium/aluminum: may affect absorption of oral formulations (not applicable to IV but noted for completeness).